Abstract
Although tamoxifen was the standard endocrine treatment for breast cancer for more than 30 years, aromatase inhibitors such as anastrozole now have an important therapeutic role in postmenopausal women. Anastrozole gained initial acceptance for use in advanced breast cancer, but subsequent studies have shown that, in early breast cancer, anastrozole is superior to tamoxifen as initial adjuvant therapy for newly diagnosed patients, while patients already receiving treatment benefit from switching to anastrozole rather than continuing with tamoxifen or from extending therapy with anastrozole after 5 years of tamoxifen. Additionally, in the neoadjuvant setting, anastrozole may reduce tumor size in patients with locally advanced disease. Current studies are focusing on possible uses of anastrozole in breast cancer prevention and combination treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
